Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$150.30 USD

150.30
680,430

+0.34 (0.23%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.

Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact

by Zacks Equity Research

Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.

BD (BDX) Launches Advanced Vascular Access Management System

by Zacks Equity Research

BD's (BDX) SiteRite 9 Ultrasound System is likely to revolutionize vascular care by enhancing clinician efficiency and setting a new standard in first-attempt success.

West Pharmaceutical's (WST) New Launch to Expand Portfolio

by Zacks Equity Research

West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.

Best Growth Stocks to Buy for December 5th

by Zacks Equity Research

LMB, DVA and PK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 5, 2023.

The Zacks Analyst Blog Highlights Cboe Global Markets, Gartner, Intel, Royal Caribbean Cruises and DaVita

by Zacks Equity Research

Cboe Global Markets, Gartner, Intel, Royal Caribbean Cruises and DaVita are included in this Analyst Blog.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.

McKesson (MCK) Announces Availability of FDA-Cleared Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.

Nalak Das headshot

Top 5 High-Flying S&P 500 Stocks of November With More Upside

by Nalak Das

Five S&P 500 stocks with more potential are: IT, INTC, RCL, CBOE, DVA.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.

Philips (PHG) Adds Smart Fit Coils to Boost Diagnostic Imaging

by Zacks Equity Research

Philips (PHG) launches three MR Smart Fit coils, namely TorsoCardiac 1.5T, 1.5T shoulder and Knee 3.0T, enhancing flexibility, reducing patient setup time and improving image quality resolution.

Revvity (RVTY) Launches New Molecular Testing for Newborns

by Zacks Equity Research

Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

3 Reasons to Retain Inspire Medical (INSP) Stock for Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome

by Zacks Equity Research

Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.

Zacks.com featured highlights DaVita, Brinker International, CNA Financial and Integer Holdings

by Zacks Equity Research

DaVita, Brinker International, CNA Financial and Integer Holdings have been highlighted in this Screen of The Week article.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Patterson Companies (PDCO) Q2 Earnings Miss, EPS View Lowered

by Zacks Equity Research

Patterson Companies' (PDCO) second-quarter fiscal 2024 results reflect improvement in Dental Consumable sales, which were offset by lower Dental Equipment sales. Animal health sales improve.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like DVA, EAT, CNA and ITGR that are seeing price strength have a high chance of carrying the momentum forward.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Philips (PHG) Bolsters Diagnostic Imaging With New Launches

by Zacks Equity Research

Philips (PHG) unveils an array of AI-enabled innovations at RSNA23 to enhance diagnostic imaging capabilities across healthcare providers.

Urmimala Biswas headshot

5 Finest PEG-Based Value Stocks to Buy Now

by Urmimala Biswas

Here are five stocks that match our screening criteria ¿¿¿ FOXA, DVA, LDOS, BLD and ITRI.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.